Spark Therapeutics Logo
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
January 27, 2023 09:00 ET | Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the...
Spark Therapeutics Logo
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
December 12, 2022 12:00 ET | Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...
Spark Therapeutics Logo
Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor
February 23, 2022 10:29 ET | Spark Therapeutics, Inc.
Under Jeff Marrazzo’s leadership, Spark launched world’s first FDA-approved gene therapy for a genetic disease. He also spearheaded Spark’s $4.8 billion acquisition by Roche. Company’s...
Spark Therapeutics Logo
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
December 17, 2021 08:00 ET | Spark Therapeutics, Inc.
Roche affirms its long-term commitment to Philadelphia as gene therapy center of excellence Spark signs 99-year ground lease of Drexel University’s property, to create a premier environment for...
Spark Therapeutics Logo
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients
November 17, 2021 17:01 ET | Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Logo
Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01
October 12, 2021 07:30 ET | Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Logo
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date
July 21, 2021 10:12 ET | Spark Therapeutics, Inc.
Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011 Across all dose cohorts, there was a 91.2% reduction in...
Spark Therapeutics Logo
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
April 13, 2021 08:30 ET | Spark Therapeutics, Inc.
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies...
Spark Therapeutics Logo
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
February 25, 2021 07:30 ET | Spark Therapeutics, Inc.
PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
Spark Therapeutics Logo
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
February 05, 2021 10:51 ET | Spark Therapeutics, Inc.
Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X1011 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable...